SCYX Scynexis Inc
- Stocks
- Healthcare
- NASDAQ: SCYX
Price (delayed)
$0.6811
Market cap
$26.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.56
Enterprise value
$21.58M
SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly
Highlights
Scynexis's quick ratio has surged by 95% QoQ and by 55% YoY
Scynexis's debt has plunged by 85% from the previous quarter and by 84% YoY
The company's net income has shrunk by 127% YoY and by 27% QoQ
The company's EPS has shrunk by 126% YoY and by 27% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.scynexis.com
Peers:
CPRX
Key stats
What are the main financial stats of SCYX
Market
Valuations
Earnings
Shares outstanding
39.02M
Market cap
$26.58M
Enterprise value
$21.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
12.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.2
Revenue
$2.63M
Gross profit
$2.63M
Operating income
-$36.22M
Net income
-$27.09M
EBIT
-$26.67M
EBITDA
-$26.67M
Free cash flow
-$27.47M
Per share
Balance sheet
Liquidity
EPS
-$0.56
EPS diluted
-$0.56
Free cash flow per share
-$0.56
Book value per share
$1.3
Revenue per share
$0.05
TBVPS
$1.37
Total assets
$67.92M
Total liabilities
$17.38M
Debt
$2.49M
Equity
$50.53M
Working capital
$43.26M
Debt to equity
0.05
Current ratio
5.83
Quick ratio
5.68
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
-1,014%
Gross margin
100%
Net margin
-1,030%
Operating margin
-1,377.2%
Return on assets
-29.7%
Return on equity
-48.3%
Return on invested capital
-42.4%
Return on capital employed
-45.2%
Return on sales
-1,014%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SCYX stock price
How has the Scynexis stock price performed over time
Intraday
-1.3%
1 week
-6.71%
1 month
-2.84%
1 year
-66.61%
YTD
-43.71%
QTD
0.93%
Financial performance
How have Scynexis's revenue and profit performed over time
Revenue
$2.63M
Gross profit
$2.63M
Operating income
-$36.22M
Net income
-$27.09M
Gross margin
100%
Net margin
-1,030%
SCYX's operating income has shrunk by 149% YoY but it is up by 2.4% QoQ
The company's net income has shrunk by 127% YoY and by 27% QoQ
The gross profit has shrunk by 98% YoY and by 30% QoQ
Scynexis's revenue has shrunk by 98% YoY and by 30% QoQ
Price vs fundamentals
How does SCYX's price correlate with its fundamentals
Growth
What is Scynexis's growth rate over time
Valuation
What is Scynexis stock price valuation
P/E
N/A
P/B
0.53
P/S
12.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.2
The company's EPS has shrunk by 126% YoY and by 27% QoQ
SCYX's price to book (P/B) is 84% lower than its 5-year quarterly average of 3.3 and 41% lower than its last 4 quarters average of 0.9
The equity has declined by 32% year-on-year and by 8% since the previous quarter
Scynexis's revenue has shrunk by 98% YoY and by 30% QoQ
The P/S is 20% lower than the 5-year quarterly average of 16.1
Efficiency
How efficient is Scynexis business performance
The return on equity has dropped by 140% year-on-year and by 41% since the previous quarter
Scynexis's return on assets has shrunk by 140% YoY and by 45% QoQ
SCYX's return on invested capital has dropped by 137% year-on-year and by 40% since the previous quarter
The company's return on sales has shrunk by 87% QoQ
Dividends
What is SCYX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SCYX.
Financial health
How did Scynexis financials performed over time
Scynexis's quick ratio has surged by 95% QoQ and by 55% YoY
The current ratio has soared by 94% from the previous quarter and by 57% YoY
Scynexis's debt is 95% less than its equity
Scynexis's debt has plunged by 85% from the previous quarter and by 84% YoY
The company's debt to equity has shrunk by 83% QoQ and by 76% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.